NVS
Income statement / Annual
Last year (2023), Novartis AG's total revenue was $46.66 B,
a decrease of 9.97% from the previous year.
In 2023, Novartis AG's net income was $14.85 B.
See Novartis AG’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$46.66 B
|
$51.83 B
|
$52.88 B
|
$49.90 B
|
$48.68 B
|
$53.17 B
|
$50.14 B
|
$49.44 B
|
$50.39 B
|
$53.63 B
|
| Cost of Revenue |
$12.47 B |
$15.49 B |
$15.87 B |
$15.12 B |
$14.43 B |
$18.41 B |
$17.18 B |
$17.52 B |
$17.40 B |
$17.35 B |
| Gross Profit |
$34.19 B |
$36.34 B |
$37.01 B |
$34.78 B |
$34.25 B |
$34.76 B |
$32.96 B |
$31.92 B |
$32.98 B |
$36.29 B |
| Gross Profit Ratio |
0.73 |
0.7 |
0.7 |
0.7 |
0.7 |
0.65 |
0.66 |
0.65 |
0.65 |
0.68 |
| Research and Development
Expenses |
$11.37 B
|
$10.00 B
|
$9.54 B
|
$8.98 B
|
$9.40 B
|
$9.07 B
|
$8.97 B
|
$9.04 B
|
$8.94 B
|
$9.09 B
|
| General & Administrative
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$16.47 B
|
$2.14 B
|
$2.19 B
|
$2.48 B
|
$2.62 B
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$12.86 B
|
$12.00 B
|
$11.77 B
|
$12.38 B
|
| Selling, General &
Administrative Expenses |
$12.52 B
|
$14.25 B
|
$14.89 B
|
$14.20 B
|
$14.37 B
|
$16.47 B
|
$15.00 B
|
$14.19 B
|
$14.25 B
|
$14.99 B
|
| Other Expenses |
-$209.00 M |
$2.90 B |
$895.00 M |
$1.45 B |
$1.40 B |
$1.05 B |
$362.00 M |
$417.00 M |
$824.00 M |
$1.12 B |
| Operating Expenses |
$24.42 B |
$27.15 B |
$25.32 B |
$24.63 B |
$25.17 B |
$26.59 B |
$24.33 B |
$23.65 B |
$24.01 B |
$25.20 B |
| Cost And Expenses |
$36.89 B |
$42.63 B |
$41.19 B |
$39.75 B |
$39.59 B |
$45.00 B |
$41.51 B |
$41.17 B |
$41.41 B |
$42.55 B |
| Interest Income |
$627.00 M |
$379.00 M |
$71.00 M |
$91.00 M |
$245.00 M |
$294.00 M |
$110.00 M |
$43.00 M |
$33.00 M |
$33.00 M |
| Interest Expense |
$855.00 M |
$837.00 M |
$811.00 M |
$869.00 M |
$850.00 M |
$957.00 M |
$777.00 M |
$707.00 M |
$655.00 M |
$704.00 M |
| Depreciation &
Amortization |
$8.28 B
|
$6.71 B
|
$5.43 B
|
$5.11 B
|
$5.83 B
|
$5.21 B
|
$5.21 B
|
$5.35 B
|
$5.58 B
|
$4.75 B
|
| EBITDA |
$18.47 B
|
$16.39 B
|
$33.06 B
|
$17.21 B
|
$15.62 B
|
$21.75 B
|
$15.90 B
|
$15.04 B
|
$14.36 B
|
$17.73 B
|
| EBITDA Ratio |
0.4 |
0.32 |
0.63 |
0.34 |
0.32 |
0.41 |
0.32 |
0.3 |
0.29 |
0.33 |
| Operating Income Ratio
|
0.21
|
0.18
|
0.51
|
0.2
|
0.19
|
0.15
|
0.17
|
0.17
|
0.18
|
0.21
|
| Total Other
Income/Expenses Net |
-$227.00 M
|
-$826.00 M
|
-$811.00 M
|
-$274.00 M
|
-$146.00 M
|
$6.37 B
|
$1.06 B
|
$233.00 M
|
$266.00 M
|
$1.92 B
|
| Income Before Tax |
$9.12 B |
$8.37 B |
$26.14 B |
$9.88 B |
$8.94 B |
$13.84 B |
$9.00 B |
$7.82 B |
$8.13 B |
$12.27 B |
| Income Before Tax Ratio
|
0.2
|
0.16
|
0.49
|
0.2
|
0.18
|
0.26
|
0.18
|
0.16
|
0.16
|
0.23
|
| Income Tax Expense |
$551.00 M |
$1.42 B |
$2.12 B |
$1.81 B |
$1.79 B |
$1.22 B |
$1.30 B |
$1.12 B |
$1.11 B |
$1.55 B |
| Net Income |
$14.85 B |
$6.96 B |
$24.02 B |
$8.07 B |
$7.15 B |
$12.61 B |
$7.70 B |
$6.71 B |
$17.78 B |
$10.21 B |
| Net Income Ratio |
0.32 |
0.13 |
0.45 |
0.16 |
0.15 |
0.24 |
0.15 |
0.14 |
0.35 |
0.19 |
| EPS |
7.15 |
3.19 |
10.71 |
3.54 |
3.12 |
5.44 |
3.28 |
2.82 |
7.4 |
4.21 |
| EPS Diluted |
7.1 |
3.17 |
10.63 |
3.52 |
3.08 |
5.38 |
3.25 |
2.8 |
7.29 |
4.13 |
| Weighted Average Shares
Out |
$2.08 B
|
$2.18 B
|
$2.24 B
|
$2.28 B
|
$2.29 B
|
$2.32 B
|
$2.35 B
|
$2.38 B
|
$2.40 B
|
$2.43 B
|
| Weighted Average Shares
Out Diluted |
$2.09 B
|
$2.20 B
|
$2.26 B
|
$2.30 B
|
$2.32 B
|
$2.34 B
|
$2.37 B
|
$2.40 B
|
$2.44 B
|
$2.47 B
|
| Link |
|
|
|
|
|
|
|
|
|
|
